8,621 results match your criteria schizophrenia randomized

Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.

J Psychiatr Res 2021 Apr 30;138:444-452. Epub 2021 Apr 30.

Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.

Background: We examined the efficacy and safety of using antipsychotic medication for schizophrenia using only randomized trials of antipsychotic for schizophrenia conducted in Japan to avoid the biological and environmental heterogeneities caused by pooling data from various races and ethnicities.

Methods: We searched for eligible studies on Embase, PubMed, and CENTRAL. Primary outcomes were improvement in Positive and Negative Syndrome Scale total score (PANSS-T) and all-cause discontinuation. Read More

View Article and Full-Text PDF

Feasibility and acceptability of remotely accessed cognitive remediation for schizophrenia in public health settings.

Psychiatry Res 2021 Apr 21;301:113956. Epub 2021 Apr 21.

Brown School of Social Work, Washington University in St. Louis, Goldfarb Hall, Room 358, Campus Box 1196, One Brookings Drive, St. Louis, MO 63130, United States.

Cognitive remediation (CR) is an evidence-based therapy used to improve cognition in people with schizophrenia. However, it often requires multiple in-person clinic sessions per week, which can limit scalability. This mixed methods study considered the feasibility and acceptability of a hybrid approach, which allowed for half the sessions to be conducted remotely as homework, without the clinician present. Read More

View Article and Full-Text PDF

The efficacy and acceptability of hybrid electroconvulsive therapy compared with standard electroconvulsive therapy for schizophrenia patients: A parallel-group, double-blind, randomized, controlled trial.

Brain Stimul 2021 May 4. Epub 2021 May 4.

Department of Psychiatry, Shenzhen Kangning Hospital, and Shenzhen Mental Health Center, Shenzhen, Guangdong, China; Brain Function and Psychosomatic Medicine Institute, Second People's Hospital of Huizhou, Huizhou, Guangdong, China. Electronic address:

View Article and Full-Text PDF

Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.

J Clin Psychopharmacol 2021 Apr 30. Epub 2021 Apr 30.

From the Division of Psychiatry NORMENT Centre of Excellence, Haukeland University Hospital Department of Clinical Medicine, Section of Psychiatry, Faculty of Medicine Department of Biological and Medical Psychology, University of Bergen Department of Addiction Medicine, Haukeland University Hospital Department of Clinical Psychology, University of Bergen, Bergen, Norway Medizinische Universität Innsbruck, Innsbruck, Austria TIPS Centre for Clinical Research in Psychosis, Psychiatric Division, Stavanger University Hospital Faculty of Health, Network for Medical Sciences, University of Stavanger, Stavanger Department of Mental Health, St Olav's University Hospital Department of Mental Health, Faculty of Medicine and Health Science, NTNU, Trondheim, Norway.

Background: Most studies investigating antipsychotic effectiveness report either total psychopathology or symptom cluster findings. Studies focusing on a separate symptom, such as hallucinations, a hallmark symptom in schizophrenia, are scarce.Therefore, the current study aims to compare the antihallucinatory effectiveness of 3 pharmacologically different antipsychotics: olanzapine, amisulpride, and aripiprazole. Read More

View Article and Full-Text PDF

Sensory gating in tobacco-naïve cannabis users is unaffected by acute nicotine administration.

Psychopharmacology (Berl) 2021 May 1. Epub 2021 May 1.

Department of Psychology, Saint Mary's University, Halifax, NS, Canada.

Objectives: Long-term cannabis use has been associated with the appearance of psychotic symptoms and schizophrenia-like cognitive impairments; however these studies may be confounded by concomitant use of tobacco by cannabis users. We aimed to determine if previously observed cannabis-associated deficits in sensory gating would be seen in cannabis users with no history of tobacco use, as evidenced by changes in the P50, N100, and P200 event-related potentials. A secondary objective of this study was to examine the effects of acute nicotine administration on cannabis users with no tobacco use history. Read More

View Article and Full-Text PDF

Efficacy and Safety of Multi-Session Transcranial Direct Current Stimulation on Social Cognition in Schizophrenia: A Study Protocol for an Open-Label, Single-Arm Trial.

J Pers Med 2021 Apr 19;11(4). Epub 2021 Apr 19.

National Center of Neurology and Psychiatry, Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Backgrounds: Social cognition is defined as the mental operations underlying social behavior. Patients with schizophrenia elicit impairments of social cognition, which is linked to poor real-world functional outcomes. In a previous study, transcranial direct current stimulation (tDCS) improved emotional recognition, a domain of social cognition, in patients with schizophrenia. Read More

View Article and Full-Text PDF

Scale development and an educational program to reduce the stigma of schizophrenia among community pharmacists: a randomized controlled trial.

BMC Psychiatry 2021 04 26;21(1):211. Epub 2021 Apr 26.

Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.

Background: Stigma associated with mental disorders is rooted among many pharmacists, and represents a major barrier to patient support in community-based psychiatry. We developed an assessment scale that is specifically designed to assess the level of stigma that pharmacists may have toward schizophrenia, and then examined the effects of reducing stigma with an educational program that focuses on communication with patients diagnosed with schizophrenia (PDS) using the newly developed Stigma Scale towards Schizophrenia for Community Pharmacists (SSCP).

Methods: SSCP was developed by exploratory factor analysis with promax rotation based on responses from 822 randomly selected community pharmacists. Read More

View Article and Full-Text PDF

Sustained Effect of a Brief Video in Reducing Public Stigma Toward Individuals With Psychosis: A Randomized Controlled Trial of Young Adults.

Am J Psychiatry 2021 Apr 26:appiajp202020091293. Epub 2021 Apr 26.

New York State Psychiatric Institute and Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York (Amsalem, Markowitz, Jankowski, Neria, Dixon); Department of Social and Behavioral Sciences, College of Global Public Health, New York University, New York (Yang, Lieff); Department of Epidemiology (Yang) and Department of Biostatistics (Valeri), Columbia University Mailman School of Public Health, New York; Department of Epidemiology, Columbia University Irving Medical Center, New York (Neria).

Objective: Public stigma is a barrier to care and increases the duration of untreated psychosis among individuals with first-episode psychosis. The authors recently demonstrated the efficacy of a 90-second social contact-based video intervention in reducing such stigma. That proof-of-concept study was the first to employ so brief an antistigma intervention in a sample of young adults. Read More

View Article and Full-Text PDF

Randomized trial of a brief peer support intervention for individuals with schizophrenia transitioning from hospital to community.

Schizophr Res 2021 Apr 22;231:214-220. Epub 2021 Apr 22.

University of Toronto Department of Psychiatry, Canada. Electronic address:

This phase 2 randomized trial examined the outcomes of a brief, transitional, peer support intervention designed to address the poor outcomes that are common for individuals with schizophrenia spectrum illnesses in the period immediately following hospitalization. In the context of treatment-as-usual, participants were provided with a peer support intervention, 'the Welcome Basket,' in which participants received 1-2 sessions of peer support in the two weeks before discharge and met weekly for a month post-discharge. The study also piloted a brief version of this intervention with only one community session post-discharge with the same pre-discharge process. Read More

View Article and Full-Text PDF

Left prefrontal transcranial direct-current stimulation reduces symptom-severity and acutely enhances working memory in schizophrenia.

Neurosci Lett 2021 Apr 21;755:135912. Epub 2021 Apr 21.

The Clinical Research Center for Brain Sciences, Herzog Medical Center, Jerusalem, Israel.

Recent studies indicated that left dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) may improve clinical status and cognitive functioning in schizophrenia patients. The current study examined the effects of left prefrontal anodal tDCS on symptom-severity and on working memory performance in schizophrenia (SZ) patients. We conducted a double-blind, randomized sham-controlled parallel-group trial. Read More

View Article and Full-Text PDF

Effects of deep transcranial magnetic stimulation (dTMS) on cognition.

Neurosci Lett 2021 Apr 20;755:135906. Epub 2021 Apr 20.

National Institute of Mental Health, Topolová 748, Klecany, 25067, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, Prague 10, 10100, Czech Republic. Electronic address:

Deep transcranial magnetic stimulation (dTMS) is a modern non-invasive brain stimulation method demonstrated as effective in the treatment of major depression and obsessive-compulsive disorder (OCD). This review aims to survey present knowledge concerning the cognitive function changes identified in dTMS research. A systematic literature search in PubMed and Google Scholar was performed and 23 out of 64 studies on dTMS and cognitive functioning were included in the review. Read More

View Article and Full-Text PDF

Intranasal oxytocin for negative symptoms of schizophrenia: systematic review, meta-analysis and dose-response meta-analysis of randomized controlled trials.

Int J Neuropsychopharmacol 2021 Apr 23. Epub 2021 Apr 23.

Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Switzerland.

Background: Negative symptoms are a core aspect of psychopathology in schizophrenia. Currently available pharmacological agents have proven minimally efficacious for remediating negative symptoms. A promising treatment avenue is the intranasal administration of the neuropeptide oxytocin. Read More

View Article and Full-Text PDF

Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study.

Psychiatry Clin Neurosci 2021 Apr 23. Epub 2021 Apr 23.

Japan Depression Center, Japan.

Aim: To evaluate the efficacy of lurasidone in acute schizophrenia in Japan and other countries.

Methods: Subjects, ages 18-74, diagnosed with schizophrenia were to be randomized to lurasidone 40 mg/day or placebo. The primary efficacy endpoint was change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score at Week 6. Read More

View Article and Full-Text PDF

Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms.

Front Psychiatry 2021 6;12:631589. Epub 2021 Apr 6.

Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.

Schizophrenia is a severe and enduring disease and is one of the leading causes of disability worldwide. Cognitive impairment is a core clinical symptom that plays a crucial role in functional outcomes and prognosis, thus making it a relevant treatment target. The aim of this study was to assess the efficacy of alpha-7 nicotinic acetylcholine receptor agonists (α7 nAChR) as adjunctive treatment to enhance cognition and ameliorate negative symptoms in patients with schizophrenia. Read More

View Article and Full-Text PDF

Effect of TAAR1/5-HT agonist SEP-363856 on REM sleep in humans.

Transl Psychiatry 2021 Apr 20;11(1):228. Epub 2021 Apr 20.

Sunovion Pharmaceuticals Inc, Marlborough, MA, USA.

SEP-363856 is a trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT) agonist, currently in Phase 3 clinical trials for the treatment of schizophrenia. Although SEP-363856 activates TAAR1 and 5-HT receptors in vitro, an accessible marker of time- and concentration-dependent effects of SEP-363856 in humans is lacking. In rodents, SEP-363856 has been shown to suppress rapid eye movement (REM) sleep. Read More

View Article and Full-Text PDF

Less is more: Deprescribing anticholinergic medications in persons with severe mental illness.

Ann Clin Psychiatry 2021 05;33(2):80-92

University of Pittsburgh School of Medicine, UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, USA.

Background: Long-term prescribing of anticholinergic medications (ACM) for antipsychotic-associated extrapyramidal symptoms (EPS) is not recommended, yet is widely prevalent. Adverse effects of ACM include memory impairment, dry mouth, constipation, blurred vision, urinary retention, and tachycardia, which can seriously impact quality of life. This quality improvement deprescription project sought to reduce chronic ACM use in patients with serious mental illness (SMI). Read More

View Article and Full-Text PDF

Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

JAMA Psychiatry 2021 Apr 20. Epub 2021 Apr 20.

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Importance: Cognitive impairment is a core feature of schizophrenia, with negative consequences on functional outcomes. Although cognitive remediation (CR) is effective and mentioned in treatment guidance for schizophrenia, its active ingredients and ideal candidates are still debated.

Objective: To provide a comprehensive update on CR effectiveness for cognition and functioning in schizophrenia and analyze the core ingredients of efficacy and role of patient characteristics. Read More

View Article and Full-Text PDF

[Contribution of electronic cigarettes in smoking patients with psychotic disorders. A literature review].

Encephale 2021 Apr 13. Epub 2021 Apr 13.

Unité de recherche clinique Pierre-Deniker, centre hospitalier Henri-Laborit, université de Poitiers, 370, avenue Jacques-Cœur, CS 10587, 86021 Poitiers cedex, France.

Objectives: This systematic literature review focused on patients suffering from schizophrenia (SZ), psychotic disorders or mental illness (MI) including SZ. It was interested in data on prevalence of electronic cigarette (EC) use, patient perceptions and expectations, as well as caregivers' attitudes towards the EC and its benefit in helping to stop or reduce smoking.

Method: The research was carried out on Medline for the period 2000-2020. Read More

View Article and Full-Text PDF

A Critical Systematic Review of Current Evidence on the Effects of Physical Exercise on Whole/Regional Grey Matter Brain Volume in Populations at Risk of Neurodegeneration.

Sports Med 2021 Apr 16. Epub 2021 Apr 16.

Exercise Biology, Department of Public Health, Aarhus University, Aarhus, Denmark.

Background: Despite the intriguing potential of physical exercise being able to preserve or even restore brain volume (grey matter volume in particular)-a tissue essential for both cognitive and physical function-no reviews have so far synthesized the existing knowledge from randomized controlled trials investigating exercise-induced changes of the brain's grey matter volume in populations at risk of neurodegeneration. Our objective was to critically review the existing evidence regarding this topic.

Methods: A systematic search was carried out in MEDLINE and EMBASE databases primo April 2020, to identify randomized controlled trials evaluating the effects of aerobic training, resistance training or concurrent training on brain grey volume changes (by MRI) in adult clinical or healthy elderly populations. Read More

View Article and Full-Text PDF

Misreporting of Results of Research in Psychiatry.

Schizophr Bull 2021 Apr 16. Epub 2021 Apr 16.

Stanley Medical Research Institute, Kensington, MD, USA.

Few studies address publication and outcome reporting biases of randomized controlled trials (RCTs) in psychiatry. The objective of this study was to determine publication and outcome reporting bias in RCTs funded by the Stanley Medical Research Institute (SMRI), a U.S. Read More

View Article and Full-Text PDF

A prospective multicenter assessor-blinded randomized controlled study to compare the efficacy of short versus long protocols of electroconvulsive therapy as an augmentation strategy to clozapine in patients with ultra-resistant schizophrenia (SURECT study).

Trials 2021 Apr 15;22(1):284. Epub 2021 Apr 15.

University Department of Psychiatry, Centre d'Excellence Thérapeutique- Institut de Psychiatrie, Centre Hospitalier du Rouvray, Sotteville-lès-Rouen, France.

Background: Although clozapine is the most effective antipsychotic drug for treatment-resistant schizophrenia, it leads to a poor or partial response in 40 to 70% of patients. Augmentation of clozapine with electroconvulsive therapy (ECT) is a highly effective and relatively safe treatment for these clozapine-resistant patients. However, parameters are not yet well specified, such as the optimal number of sessions, their frequency, and the relevance of maintenance ECT. Read More

View Article and Full-Text PDF

Cognitive training with fully immersive virtual reality in patients with neurological and psychiatric disorders: A systematic review of randomized controlled trials.

Psychiatry Res 2021 Apr 6;300:113928. Epub 2021 Apr 6.

Neurocognition and Emotion in Affective Disorders (NEAD) Group, Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; Department of Psychology, University of Copenhagen, Copenhagen, Denmark. Electronic address:

Cognitive impairment occurs across several neuropsychiatric diseases and impede everyday functioning and quality of life. Fully immersive Virtual Reality (VR) aid motivation and engagement and therefore has a potential to help overcome the obstacles in the field of cognitive rehabilitation. The aim of this systematic review is to investigate whether VR can be a useful intervention in cognitive rehabilitation transdiagnostically. Read More

View Article and Full-Text PDF

Mononitrate Isosorbide as an Adjunctive Therapy in Schizophrenia: A Randomized Controlled Crossover Trial.

J Clin Psychopharmacol 2021 May-Jun 01;41(3):260-266

Department of Psychiatry, Interdisciplinary Lab of Clinical Neurosciences (LiNC), and Schizophrenia Program (PROESQ), Federal São Paulo University (Unifesp), São Paulo, Brazil.

Background: Schizophrenia is a complex disabling mental disorder, and many patients present poor response to available treatments. Accumulating evidence about the role of the glutamate/nitric oxide pathway in mediating the positive and negative symptoms of schizophrenia suggests potential benefits of drugs that modulate this system. The aim of this study was to test the efficacy of isosorbide mononitrate (ISMN) as an adjunctive therapy for symptomatic outpatients with schizophrenia. Read More

View Article and Full-Text PDF

Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study.

Psychol Med 2021 Apr 15:1-8. Epub 2021 Apr 15.

Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Background: Current evidence on antipsychotic treatment and risk of psychiatric hospitalization in first-episode schizophrenia (FES) is largely based on the findings from randomized clinical trials (RCTs). However, the generalization of the findings to real-world patients is limited due to inherent caveats of the RCT. We aimed to investigate the treatment discontinuation and risk of psychiatric hospitalization using a nationwide population database. Read More

View Article and Full-Text PDF

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial.

Transl Psychiatry 2021 Apr 14;11(1):219. Epub 2021 Apr 14.

Centre for Addiction and Mental Health, Toronto, ON, Canada.

Patients with schizophrenia have exceedingly high rates of metabolic comorbidity including type 2 diabetes and lose 15-20 years of life due to cardiovascular diseases, with early accrual of cardiometabolic disease. In this study, thirty overweight or obese (Body Mass Index (BMI) > 25) participants under 40 years old with schizophrenia spectrum disorders and early comorbid prediabetes or type 2 diabetes receiving antipsychotic medications were randomized, in a double-blind fashion, to metformin 1500 mg/day or placebo (2:1 ratio; n = 21 metformin and n = 9 placebo) for 4 months. The primary outcome measures were improvements in glucose homeostasis (HbA1c, fasting glucose) and insulin resistance (Matsuda index-derived from oral glucose tolerance tests and homeostatic model of insulin resistance (HOMA-IR)). Read More

View Article and Full-Text PDF

Cognitive remediation and professional insertion of people with schizophrenia: RemedRehab, a randomized controlled trial.

Eur Psychiatry 2021 Apr 15;64(1):e31. Epub 2021 Apr 15.

Psychosocial Rehabilitation Resource Center (CRR) and Reference Center (SUR-CL3R), Le Vinatier Hospital, Lyon, France.

Background: People suffering from schizophrenia cannot easily access employment in European countries. Different types of vocational programs coexist in France: supported employment, sheltered employment (ShE), and hybrid vocational programs. It is now acknowledged that the frequent cognitive impairments constitute a major obstacle to employment for people with schizophrenia. Read More

View Article and Full-Text PDF

Aripiprazole IM depot as an option for the treatment of bipolar disorder.

Expert Opin Pharmacother 2021 Apr 13:1-10. Epub 2021 Apr 13.

Department of Neuropsychiatry, Villa Von Siebenthal Neuropsychiatric Hospital, Genzano Di Roma, Italy.

: Long-acting injectable (LAI) antipsychotic drugs are developed to reduce daily intake need and to overcome treatment non-adherence. Aripiprazole IM depot refers to two long-acting aripiprazole formulations, once monthly monohydrate (AOM) and aripiprazole lauroxil. AOM has been approved for schizophrenia since 2012 and for bipolar disorder since 2017. Read More

View Article and Full-Text PDF

Effectiveness of community-based interventions for patients with schizophrenia spectrum disorders: a study protocol for a systematic review.

Syst Rev 2021 Apr 13;10(1):106. Epub 2021 Apr 13.

Department of Nursing, Far East University, Chungchungbuk-do, South Korea.

Background: Schizophrenia requires a community-based intervention approach combined with standard treatment to prevent relapses. A literature review is required to understand the effectiveness of community-based interventions and to enhance quality in countries where they have not been fully established. This is a protocol for a systematic review of the effectiveness of community-based interventions for patients with schizophrenia spectrum disorders. Read More

View Article and Full-Text PDF

Randomized controlled trial of an adjunctive sulforaphane nutraceutical in schizophrenia.

Schizophr Res 2021 Apr 8;231:142-144. Epub 2021 Apr 8.

Johns Hopkins School of Medicine, Stanley Neurovirology Laboratory, 600 North Wolfe St., Baltimore, MD 21205, United States of America.

View Article and Full-Text PDF

The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study.

Schizophr Res 2021 Apr 7;231:100-107. Epub 2021 Apr 7.

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain.

Objective: The identification of predictors of psychosis remission could guide early clinical decision-making for treatment of first-episode schizophrenia (FES).

Methods: We analyzed two non-independent subsamples of patients with FES ages 18-40 years from the OPTiMiSE study dataset to investigate the demographic and clinical factors that might help to differentiate "late" remitters (i.e. Read More

View Article and Full-Text PDF